The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants

By Staff Reporters

***

***

• Markets: Stocks notched their fourth winning day in a row yesterday as investors digested the news that the Fed was split about future rate hikes at its last meeting while waiting for this morning’s report on how much consumer prices rose last month.
• Ozempic continues eating into investors’ appetites for other industries. Its maker, Novo Nordisk, rose on the news that the diabetes drug may help treat kidney failure, but dialysis providers DaVita and Fresenius Medical Care plunged.

***

Earnings season is back: PepsiCo, Delta, Dominos, and big banks headline the start of earnings season, one that will have investors looking at how slowing inflation has affected the ability of companies to pad their profit margins. Pepsi’s report will be closely watched as its snack division, Frito-Lay, could be tested by the increasing popularity of weight-loss drugs like Wegovy. Major banks like JPMorgan are expected to post strong results.

CITE: https://www.r2library.com/Resource

US consumer spending: Has remained surprisingly strong despite rising interest rates, and a senior spending spree could explain it. According to the Department of Labor, Americans aged 65 and older accounted for 22% of consumer spending last year, the highest percentage since records began in 1972. It also helps that 17.7% of the US population is 65 and older, the highest on record dating to 1920. Better health, longer lifespans, and changes in attitude toward saving for a rainy day after the pandemic have boomers feeling OK about their finances.

COMMENTS APPRECIATED

Thank You

***

***

Filed under: "Ask-an-Advisor", Drugs and Pharma, Events-Planner, Funding Basics, Investing | Tagged: consumer spending, CPI, DaVita, Department Labor, DOL, earnings season, Fresenius, inflation, Novo Nordisk, Ozempic |